Literature DB >> 21624701

Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature.

Wing Yan Yuen1, Marcel F Jonkman2.   

Abstract

BACKGROUND: Squamous cell carcinoma (SCC) is the most severe complication and most common cause of death in patients with recessive dystrophic epidermolysis bullosa. The risk of developing SCC among patients with junctional epidermolysis bullosa (JEB) is unclear from the literature; however, in our center we noticed an unexpected number of SCCs among adult patients with JEB.
OBJECTIVE: To review all documented patients with JEB in whom an SCC developed, both from our epidermolysis bullosa (EB) center and those reported in the literature.
METHODS: A search in our EB registry documenting all JEB patients visiting our EB referral center from 1990 through 2010 revealed 7 JEB patients who developed 1 or more SCCs. A systematic literature search revealed 8 relevant articles documenting a total of 7 patients who developed an SCC.
RESULTS: In our EB registry we found 7 patients with JEB who developed an SCC; these were all adults classified with non-Herlitz type JEB. The frequency of developing an SCC among adult JEB patients (n = 28) in our center was therefore 25%. In the literature, we found 7 case reports of JEB complicated by SCC (also classified as JEB, non-Herlitz type), bringing the total number of documented cases to 14. The first SCC in JEB patients developed at an average age of 50 years (median, 52 years; range, 28-70 years). In 9 of 14 cases, multiple primary SCCs occurred, with a total of 45 SCCs. The SCCs are most often located on the lower extremities, in areas of chronic blistering, long-standing erosions, or atrophic scarring. Three patients (21%) developed metastases and died on average 8.9 years after diagnosis of the initial SCC. LIMITATIONS: This study was retrospective and the statistical analyses were based on a small number of patients.
CONCLUSIONS: From their third decade, adult patients with JEB have an increased risk (1:4) of developing SCC on their lower extremities. The SCCs have a high recurrence rate and follow an aggressive course that results in death in 1 of 5 patients. We recommend annual checks of all JEB patients for SCC starting at 25 years of age.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21624701     DOI: 10.1016/j.jaad.2010.07.006

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

Review 1.  Epidermolysis bullosa and the partnership with autoimmunity: what should we assimilate?

Authors:  Susanna Esposito; Sophie Guez; Francesca Manzoni; Annalisa Bosco; Donato Rigante
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Access to wound dressings for patients living with epidermolysis bullosa - an Australian perspective.

Authors:  Louise J Stevens
Journal:  Int Wound J       Date:  2012-11-22       Impact factor: 3.315

Review 3.  Oral potentially malignant disorders: an overview of more than 20 entities.

Authors:  Hamed Mortazavi; Maryam Baharvand; Masoumeh Mehdipour
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2014-03-05

Review 4.  Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases.

Authors:  H Montaudié; C Chiaverini; E Sbidian; A Charlesworth; J-P Lacour
Journal:  Orphanet J Rare Dis       Date:  2016-08-20       Impact factor: 4.123

5.  End-stage kidney disease in patient with epidermolysis bullosa - what are the treatment options? - case report.

Authors:  Michał Małecki; Maciej Domański; Kazimierz Ciechanowski
Journal:  BMC Nephrol       Date:  2017-06-14       Impact factor: 2.388

6.  Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients.

Authors:  Sara Guerrero-Aspizua; Claudio J Conti; Maria Jose Escamez; Daniele Castiglia; Giovanna Zambruno; Leila Youssefian; Hassan Vahidnezhad; Luis Requena; Peter Itin; Gianluca Tadini; Ivelina Yordanova; Ludovic Martin; Jouni Uitto; Cristina Has; Marcela Del Rio
Journal:  Orphanet J Rare Dis       Date:  2019-07-24       Impact factor: 4.123

Review 7.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

Review 8.  Epidermolysis Bullosa-A Different Genetic Approach in Correlation with Genetic Heterogeneity.

Authors:  Monica-Cristina Pânzaru; Lavinia Caba; Laura Florea; Elena Emanuela Braha; Eusebiu Vlad Gorduza
Journal:  Diagnostics (Basel)       Date:  2022-05-27

9.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

Review 10.  Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.

Authors:  May El Hachem; Giovanna Zambruno; Eva Bourdon-Lanoy; Annalisa Ciasulli; Christiane Buisson; Smail Hadj-Rabia; Andrea Diociaiuti; Carolina F Gouveia; Angela Hernández-Martín; Raul de Lucas Laguna; Mateja Dolenc-Voljč; Gianluca Tadini; Guglielmo Salvatori; Cristiana De Ranieri; Stephanie Leclerc-Mercier; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2014-05-20       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.